medwireNews: The FDA has approved extending use of dulaglutide to children and adolescents aged 10 years or older who have type 2 diabetes.
Treatment with the weekly injectable glucagon-like peptide-1 receptor agonist resulted in significant reductions in glycated hemoglobin levels, relative to placebo treatment, among young people aged 10–17 years in the AWARD-PEDS trial, published in June this year.
It did not significantly reduce weight, however.
Dulaglutide is also indicated to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for major adverse cardiovascular events in those at high risk.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group